Blood-Based Biomarkers for Lung Cancer Diagnosis and Treatment

Innovation
MU inventors have identified plasma extracellular vesicle (EV) and circulating miRNA sequences that act as minimally invasive biomarkers to diagnose Non-Small Cell Lung cancer (NSCLC) and to predict the most effective therapeutic approach.

Background
Lung cancer causes the most cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 85% of these cases. Current lung cancer screening relies on low-dose computed tomography (LDCT) scans. Due to its high false positive rate (23% – 50%), patients receiving a positive reading are sent for a more invasive biopsy procedure to confirm the results.

NSCLC patients will receive chemotherapy and/or immunotherapy, or targeted therapy based on analysis of known mutations in tissue biopsies. Despite this targeted approach to therapy, these cancers often develop drug resistance likely mediated by non-mutational miRNA-mediated mechanisms.

MU inventors have discovered EV (Hsa-miR-184, Let-7b-5p) and circulating (Hsa-miR-22-3p) miRNAs that can robustly discriminate between NSCLC patients and high-risk cancer-free controls. These blood-based miRNA biomarker can be used in isolation or in combination with LDCT to more accurately diagnose NSCLC, and can be used to predict the most effective therapeutic regime.

Applications

  • NSCLC diagnosis
  • Predict treatment efficacy for NSCLC

Advantages

  • Less risk of false positives during diagnosis
  • Avoid patient burden of inaccurate diagnosis or ineffective treatment
  • Decrease excess medical costs from inaccurate diagnosis or ineffective treatment

Patent Status
Patent pending

Inventors
Yves Chiswili Chabu

Publications
Vadla GP, Daghat B, Patterson N, et al. Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction. Sci Rep. 2022;12(1):6693. Published 2022 Apr 23. doi:10.1038/s41598-022-10598-x

Technology Manager
Brian Buntaine, MS, MBA
Senior Manager, Technology Transfer
Phone: 573-882-0470
Email: buntaineb@missouri.edu

Contact Information

Name: Brian Buntaine, MS, MBA

Title: Senior Manager, Technology Transfer

Department: MU Technology Advancement Office

Email: buntaineb@missouri.edu

Phone: 573-882-0470

Address: Columbia, Missouri 65211